Ra Pharmaceuticals begins dosing in Phase II trials of RA101495 to treat PNH

US-based Ra Pharmaceuticals has begun dosing patients in the Phase II clinical programme of its RA101495 for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).

Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news